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Abstract 
Objective 
Adherence continues to be a major challenge in healthcare but there is still limited 
understanding of all the factors which can influence adherence behaviour. The 
present study was designed to identify a range of factors associated with intentional 
non-adherence and to see if they could be formed into a psychometrically sound 
scale. 
Methods 
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Patients in three different clinical groups (Hypertension (N=175); Oncology (N=115); 
Gout (N=196)) were given the new scale together with an adherence self-report 
and/or biomarker measure. Other, more established measures of factors known to 
be associated with adherence  (BMQ, PAM, BIPQ), were also completed by patients 
for comparative and validation purposes. 
Exploratory Factor Analysis (EFA) was conducted to examine the factor structure of 
the new scale, and other statistical analyses were used for testing the psychometric 
properties of the new scale. 
Results 
EFA revealed two factors, which were labelled “Resisting illness” and “Testing 
treatment”. Both scales were found to have good psychometric properties and 
explained unique variance in adherence in all three clinical groups. 
Conclusion 
This new scale shows promise in describing and explaining some relatively novel 
factors underlying treatment non-adherence. Further work in different patient groups 
and clinical contexts is needed to confirm the factor structure and predictive value of 
these scales. 
 
Keywords: Intentional non-adherence; illness; treatment; medication; reliability; 
validity 
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INTRODUCTION 
There is widespread evidence that only 30-50% of patients are adherent to the 
medicines prescribed for long-term physical or mental health problems (1). This 
leads to reduced clinical benefit, avoidable morbidity and mortality and medication 
wastage.  Measuring adherence presents a challenge to researchers as there are 
only a few conditions, such as gout where biomarkers can provide a direct 
assessment of the amount of medicine taken. While there are electronic monitoring 
measures which can be incorporated medicines containers, these are quite costly 
and so researchers often rely on self-report measures, such as the Medication 
Adherence Report Scale (2), which was used in the present study (see below).  
Numerous interventions have been developed for facilitating medicines adherence 
(3,4) but sub-optimal adherence continues to be a massive problem in healthcare 
(1,5). Although research has shown that there are multiple factors underlying poor 
adherence (6,7), interventions still often rely on fairly simple unidimensional 
solutions, such as reminders (8), which have shown limited efficacy at best. While 
early research focused more on unintentional factors, such as forgetting (9), more 
recent studies have highlighted the importance of intentional factors, arising from 
patients’ beliefs and levels of motivation and engagement . Many studies therefore 
incorporate measures, such as the Beliefs about Medicines Questionnaire (10) and 
the Patient Activation Measure (11) to capture these additional variables ( see 
methods section). 
While the number of recognised determinants of adherence has grown, evidence 
from systematic reviews (5,12) indicates there is still considerable unexplained 
variance. Even within the domain of intentional non-adherence, there is still an 
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emphasis on the negative aspects of treatment, such as side effects, which may 
cause patients to have concerns about taking their prescribed medicine. Thus, the 
aim of the present study was to develop and test a new measure, which could 
assess different components of intentional non-adherence and to determine whether 
these could explain additional variance in behavioural and biomarker measures of 
non-adherence.  
Rather than relying on existing theoretical constructs, such as risk perceptions or 
beliefs about the pros and cons of medicines, we attempted to identify intentional 
factors that get in the way of adhering to medical treatment from the patient’s own 
perspective. We were able to do this from two distinct sources. First, from our 
previous studies, where we had data from interviews or free text responses, we 
could identify various reasons, which patients provided for not taking their medicines. 
These included factors relating to people’s illness beliefs, their perceptions of their 
own identity and the way in which medicine could have a negative impact on this 
(e.g., medicine is an unwanted reminder of being unwell).  
The second source of possible factors came from the qualitative research literature, 
which has revealed a range of reasons from in-depth interviews exploring patients’ 
views about their prescribed medicines (13,14).  An overview by Pound and 
colleagues (14) conceptualised non-adherence as a preference to minimize the 
intake of medicines and describe this as “resisting medicines” since the medicines 
can often be perceived as an unwanted reminder of illness and hence as a threat to 
self-identity. We therefore selected items to reflect this broader range of reasons for 
intentional non-adherence to ascertain their potential explanatory role in medication 
adherence, and to see if they could be grouped into any broader scales. We also 
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sought to compare the explanatory power of this new measure with some widely 
used predictors of adherence. 
METHODS 
Item selection 
Two of the authors (KP;JW) examined their own datasets as well as results from 
qualitative research on treatment adherence to select items which did not seem to be 
present in existing adherence prediction measures , such as the Beliefs about 
Medicine Questionnaire (BMQ) (10) and the Patient Activation Measure (PAM) (11). 
After generating a long list of over 30 items, we examined this for duplicates or 
ambiguous items and ended up with a shortlist of 22 items, which are shown in 
Appendix 1. 
Patient samples 
Patients from 3 different outpatient clinics provided data for this study, as follows:  
(i) 175 patients attending routine hypertension outpatient clinics at two large 
London teaching hospitals. Of these 74 (mean age = 56.2 years; 44 
female, 30 male) were used for the main psychometric analyses and 101 
(mean age 51.5 years; 62 F,39M) were from a separate study comparing 
the new measure and PAM scales (see below).  
(ii)  115 patients (mean age 62.2 years; 41 female, 68 male) attending an 
Oncology outpatient clinic at a large London teaching hospital and for 
whom medication was now their primary treatment.  
(iii) 196 patients (mean age = 61.6 years; 28 female, 168 male) with gout and 
being treated with an urate lowering medication were recruited from a 
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secondary care rheumatology clinic and a clinical research unit at the 
University of Auckland. Serum urate (SU) levels were available for 188 
participants with gout. The mean serum urate level was 0.37 mmol/L (SD = 
0.11, range: 0.18 to 0.76). For patients on urate-lowering medication a 
serum urate target of <0.36 mmol/L is recommended (15), and  54.1% (n = 
106) of the sample reached the target SU. A sub-sample of 30 patients 
(mean age = 69.62 years, SD = 8.89; 4 female, 26 male; mean SU level = 
0.35 mmol/L, SD = 0.11; 56.7% [n=17] had a target SU) also provided 4 
week follow up data for the test-retest analysis (see below). 
Patients were approached in each clinical setting and were recruited if they provided 
consent and had the ability to read in English, as no translations of the questionnaire 
were available at the time of the study. For the London samples, ethics approval was 
obtained from the proportionate review sub-committee of the Research Ethics 
Committee (North West - Greater Manchester West Research Ethics Committee - 
16/NW/0469) and the Health Research Authority . In New Zealand the study was 
approved by the University of Auckland Human Participants Ethics Committee 
(Approval No. 015963) and the Health and Disability Ethics Committees New 
Zealand (Approval No. NTX/12/EXP/130). 
 
Measures 
Intentional non-adherence 
The Intentional Non-Adherence Scale (INAS) is a 22-item scale identifying varying 
reasons why patients may intentionally stop taking their medications as prescribed.  
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The items, which are shown in Appendix 1, are preceded with the following 
instructions:  People have different experiences when taking medication and use their 
medications in ways which suit them.  Sometimes people forget or decide not to take their 
medication for various reasons.  We are interested in your personal views and experiences 
of your prescribed medication regime and the way you use your medications.  
All of the information you provide is confidential. There are no right or wrong answers to 
these questions – an answer is correct if it is true for you.  We are most interested in your 
own opinion. Please choose the response that best fits with your circumstances. 
Listed below are some of the reasons why people sometimes stop taking their medications.  
We would like to know how often each of the following statements is true for you in the past 
6 months.  For each statement please tick () one box which best represents you. 
 
Examples of items are: “To see if I really need it”, “Because I don’t like chemicals in 
my body”, “Because my body is sensitive to the effects of the medicine”, “Because I 
think the drug might become less effective over time” and “Because it reminds me 
that I have an illness”.  
Item responses are scored on a five-point Likert scale on which 1= strongly disagree, 
2= disagree, 3= neutral, 4= agree, 5= strongly agree. The final scoring of the 
questionnaire was developed and confirmed following the exploratory factor 
analyses (see below). 
Medication adherence 
In the hypertension and oncology samples, adherence to medication was assessed 
using the Medication Adherence Report Scale (MARS-5) (2), a validated 5-item 
self-report scale.  The MARS-5 consists of 5 common patterns of non-adherent 
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behaviour.  Examples of items from the adherence scale include: “I forget to take my 
medicines”, “I alter the dose of my medicines” and “I use my medicines less than is 
prescribed.”    
Item responses are scored on a five-point scale, where 1= always, 2= often, 3= 
sometimes, 4= rarely, 5= never.  Scores for each of the five items are calculated to 
give a cumulative score ranging from 5 to 25, with higher scores indicating higher 
levels of reported adherence.   
With the Gout sample, adherence to medication was assessed by a biomarker from 
a patient’s serum urate (SU) level (details in section on patient samples above). 
Since the aim of treatment is to lower the elevated SU levels, patient adherence can 
be directly assessed from their (SU) level as an objective physiological marker, 
which is a gold standard measure of adherence to urate lowering medication. 
 
Beliefs about Medicines 
In the hypertension and oncology samples, the Beliefs about Medicines 
Questionnaires-Specific (BMQ-Specific) (10) was used. This is a widely used, 
validated questionnaire comprising 10 items assessing patients' beliefs and personal 
views about the necessity of prescribed medication for controlling their illness and 
their concerns about the potential adverse consequences of taking their prescribed 
medication.  
Examples of items from the necessity scale include: “My life would be impossible 
without my medicines” and “My medicines protect me from becoming worse.” 
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Examples of items from the concerns scale include: “Having to take medicine worries 
me” and “My medicine disrupts my life.”  
Participants indicate their degree of agreement to each statement on a five-point 
Likert scale, which ranged from 1= strongly disagree to 5= strongly agree. The 
scores obtained for individual items are totalled to give a Necessity and Concerns 
scale score. Total scores for each scale range from 5 to 25, where higher scores 
signify high perceived necessity for medication and high concerns about the use of 
medication. 
 
Illness Perceptions. 
The Brief Illness Perceptions Questionnaire (BIPQ,16) was used to assess illness 
perception in the gout sample. There are 9 items, each of which assesses a 
separate component of illness perception using a 0 to 10 response scale. The 
components of illness perception assessed by the BIPQ are Consequences, 
Timeline, Personal Control, Treatment Control, Identity, Concern, Understanding and 
Emotional Response. This is a widely used scale, which has very good psychometric 
properties across a wide range of health problems (17) 
Patient Activation 
With a sample of 101 patients from the hypertension clinic, we used the Patient 
Activation Measure (PAM) (11) to assess patient activation. This 13 item scale 
assesses patient self-reported knowledge, skill, and confidence for self-management 
of one's health or chronic condition. Each item had five response options, with 
scores from 1 to 5: (1) strongly disagree, (2) disagree, (3) agree, (4) agree strongly 
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and (5) not applicable. Higher scores are indicative of greater patient confidence and 
involvement in illness self-management. 
 
Procedure  
Patients attending routine appointments within out-patient hospital clinics were 
invited to participate in a research study about their personal beliefs and experiences 
of their prescribed medication. Request for participation for potential participants 
included an email invitation letter, accompanied by a Patient Information Sheet, 
informing the participants of the purpose and nature of the research study  
The questionnaires were administered in each of the respective out-patient clinics, 
where the researcher identified and approached eligible participants in the waiting 
room, inviting them to take part in the study and complete a questionnaire either 
before or after their consultation appointment. If patients were willing to take part in 
the study, an introduction to the study was provided by the researcher, which 
described the purpose of the research, the nature of their involvement and how this 
would contribute to the research study. The researcher was in attendance 
throughout administration, providing information and support or discussing any 
concerns, if needed.  The clinician lead was also available throughout, should the 
participant need to receive any additional support and resources. 
Of the 158 oncology patients on the clinic schedule that were eligible for inclusion, 
32 refused to take part in the study, 3 individuals initially agreed to take part, but later 
withdrew without competing the questionnaire due to time constraints. Eight 
individuals asked to complete the questionnaire via the free-post self-addressed 
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postal system but none of these were returned. Overall, 115 patients completed and 
returned the questionnaire, giving an overall response rate of 115/158 (72.7%) . 
Within the hypertension clinics of the 82 study-eligible patients that were 
approached, 3 declined to take part and 5 requested to complete the questionnaire 
off-site via the free-post postal system but none of these were returned. The final 
study sample resulted in a completion response rate of 74/82 (90.2%).  
With the gout sample, 277 patients were approached and 196 agreed to participate, 
resulting in a response rate of 70.8 % 
 
Statistical analysis 
 
A maximum likelihood Exploratory Factor Analysis (EFA) with an oblique rotation 
(Promax) was conducted in STATA. Prior to performing the EFA, suitability of the 
item pool for factor analysis was assessed using Kaiser–Meyer–Olkin’s test. Factor 
retention criterion was determined by the Kaiser criterion (eigenvalues >1), scree plot 
and parallel analysis (18). Items were removed from the EFA if their factor loadings 
were non-significant or if they loaded significantly but weakly (i.e., <.40) onto more 
than one factor. The resultant factor scales were labelled in accordance with the data 
output.  
The internal reliability of the summed scores for the INAS subscales was assessed 
by calculating Cronbach's alpha. Validity was assessed by examining the 
correlations (Pearson’s correlation) between the scores from the INAS subscales 
and measures of adherence to medicine, beliefs about medicines in the Oncology 
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and Hypertension samples. Correlations between the INAS scales and the PAM 
were also examined in another sample of patients with hypertension. Additional 
multiple linear regression analyses were conducted to ascertain variables associated 
with adherence to medication (MARS scores). For the combined Oncology and 
Hypertension sample (N=185), demographic (age and gender) and clinical variables 
(diagnose group) were entered in model 1; demographic, clinical and BMQ variables 
(necessity and concern) were entered in model 2; and demographic, clinical, BMQ 
and INAS variables were entered in model 3. For the additional sample of 
hypertension patients (N=110), PAM scores were added into a single model 
including demographic, clinical, BMQ and INAS variables.  
Differences between means of INAS subscales across patient diagnoses (oncology,  
hypertension and gout) were assessed using ANOVA. 
Further Pearson’s correlation analyses were conducted using data from the Gout 
sample to examine associations between the subscales of the INAS, the BIPQ and a 
biomarker measure of adherence (serum urate levels).  An independent samples t-
test was performed to compare patients who reached or exceeded the serum target 
level of 0.36 mm/L with those whose serum levels were below the target. In a sub-
sample of 30 gout patients, the intraclass correlation coefficient (ICC) was used to 
assess test-retest reliability of the new measure over a 4 week period. 
 
RESULTS 
(a) Preliminary analysis 
Means and standard deviations for each of the INAS items are shown in appendix 1. 
Only participants with complete data for INAS (98.8%) were included in the analysis.  
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Histograms and Q-Q plots showed that four items were highly skewed and thus were 
excluded. The inter-item correlations for the remaining 18 cases were examined. All 
items correlated positively and significantly (p>.001) with each other. Kaiser–Meyer–
Olkin’s test was performed to assess the suitability of the item pool for factor 
analysis. Considering all 18 items together, the overall Kaiser–Meyer–Olkin was .94, 
exceeding the recommended minimum value of .60 (18) for conducting an EFA. 
(b) Exploratory Factor Analysis (EFA) 
A maximum likelihood EFA of the 18-items assessing intentional non- adherence to 
prescribed treatments revealed the presence of two factors with an eigenvalue 
exceeding 1, which together explained 91% of the total variance (factor 1, 83%; 
factor 2, 8%). Although factor 2 only explained a small proportion of total variance, 
the scree-plot, parallel analysis and eigenvalue rule all suggested that two factors 
should be extracted. The factor matrix showed that 8 items loaded on the first factor 
(all >0.6) and 5 items loaded on the second factor (all >0.6). Five items loaded 
significantly on both factors, and thus were discarded. Re-factoring on the remaining 
13 items produced a similar two factor structure explaining 93% of the variance. The 
correlation between the two factors was .65. 
The final 2-factor structure of the 13-item scale is shown in Table 1. The first factor 
comprised 8 items linking the decision not to take treatment with not wanting to be 
reminded of one’s illness, the association of medication with illness and the desire to 
feel ‘normal’. This factor was labelled “Resisting Illness”(RI). The second factor has 
been labelled “Testing Treatment (TT)” as it comprised 5 items assessing reasons 
for not taking treatment based on the person’s attempts to see if they can get away 
with taking less or no treatment.  
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( c) Reliability  
The two INAS sub-scales achieved high levels of internal consistency. For the 8-
items forming the Resisting Illness (RI) scale, the Cronbach alpha co-efficient 
was .95 , and for the 5-items forming the  Testing treatment (TT) scale the alpha 
was .93.  
In the 30 participants with gout who were re-assessed after a 4-week period, test-
retest reliability for the Testing treatment scale showed an intraclass correlation 
(ICC) of .97 and for the Resisting illness scale the ICC was .95. 
(d) Validity 
The validity of the 2 INAS subscales was evaluated in a number of ways. First, we 
wanted to see whether they correlated with both self-reported and biomarker 
measures of treatment adherence. Second, we wanted to examine possible 
associations with a range of measures, which have been found to explain adherence 
and self-management behaviours, and to compare the explanatory power of the 
INAS scales with these measures. Finally, we wanted to determine the extent to 
which the INAS scores discriminated between the three different clinical groups from 
whom we collected data.  
 
Adherence 
Self-reported adherence  
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Correlations between the two INAS subscales and the MARS are shown in Table 2. 
In the combined hypertension and oncology sample, both INAS subscales 
significantly and negatively correlated with self-reported adherence to medicine. Very 
similar patterns of correlation were found for these two patient groups but these 
effects were slightly stronger in the Oncology sample (r=-.57 and .-61, TT and RI 
respectively) compared with the Hypertension sample (r=-.53 and -43,  TT and RI 
respectively).   
Biomarker measure of adherence 
In the Gout sample, moderate but significant positive correlations were found 
between serum urate levels and both the Testing Treatment (r=.42) and Resisting 
Illness (r=.48) subscales of the INAS (see Table 2). An independent-sample t-test 
showed that gout participants who had a SU of 0.36 mmol/L or above (RI subscale: 
M = 16.48, SD = 7.04; TT subscale: M = 10.44, SD = 5.44) compared to participants 
who had a SU below the target level (RI subscale: M = 12.12, SD = 6.09; TT 
subscale: M = 7.59, SD = 4.10) had a significantly higher value on both subscales of 
the INAS (resisting illness subscale: t[160.54] = -4.54 , p<.001; testing treatment 
subscale: t[146.04] = -3.95 , p<.001).  
 
Beliefs about medicines, illness perceptions and patient activation. 
In the hypertension and oncology samples, patients completed the BMQ together 
with the INAS and the MARS. We did this to examine the extent to which the INAS 
subscales overlapped with the Necessity and Concerns scales of the BMQ. The 
results showed a very similar pattern of correlations for the group as a whole and for 
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both patient groups (see Table 2). Both INAS scales correlated moderately with the 
BMQ Concerns scale, emphasising that the INAS items were tapping into various 
worries that patients had about their medicines but that there was still considerable 
unexplained variance. In contrast, no correlations were found with the BMQ 
Necessity scale. In order to compare the variance in adherence self-report explained 
by the INAS and BMQ, we conducted a multiple regression analysis. The results 
reported in Table 3 show that while BMQ Concerns was significantly associated with 
MARS scores after controlling for demographic and clinical variables, this significant 
association disappeared when the INAS scores were entered in model 3.  Both INAS 
subscales were found to be significantly associated with MARS scores after 
controlling for demographic, clinical and BMQ variables. The final model explained 
37% of the variance in the MARS score.  
The gout sample also completed the BIPQ and there we found smallish correlations 
with a number of the different components of illness perception. Both INAS scales 
correlated with the Illness Identity, Consequences, and Emotional representations 
scales, and the INAS Testing treatment scale was also correlated with Illness 
Concerns (see Table 2). 
We also wanted to ensure that the INAS scales were sufficiently distinct from various 
self-regulatory constructs, such as personal control and patient activation. In the gout 
sample, it can be seen that there are no significant correlations with BIPQ Personal 
Control (Table 2). Similarly, in a sample of 101 hypertensive patients, no correlations 
were found with the PAM. In this sample we also conducted a multiple linear 
regression to evaluate whether patient activation, medication beliefs and reasons for 
intentional non-adherence predicted medication adherence while controlling for age 
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and gender. Regression results indicated the seven variables predicted 44.2% of the 
variance but only the INAS Resisting illness and Testing treatment scales 
significantly predicted medication adherence. Table 3 summarizes the results of the 
multiple linear regression.  
 
(c) Discriminant validity 
Means (SD) for the two INAS subscales according to patient diagnoses (oncology, 
hypertension and gout) can be found in Table 4. A series of one-way ANOVA 
showed differences across patient diagnoses in both INAS subscales. Post hoc 
comparisons with Scheffe tests showed that the mean differences between the 
oncology and hypertension groups were not significantly different (p .86 and p .99 for 
Resisting Illness and Testing Treatment, respectively), whereas the mean 
differences between gout patients and oncology and hypertension patients were 
statistically different on both subscales (p <.001).  
DISCUSSION 
This paper describes the preliminary development of a new scale designed to 
assess different aspects of intentional non-adherence. The items were chosen to 
assess a range of different reasons, which patients may give for deciding not to take 
their medicines as prescribed. Although these items are not strongly endorsed, they 
show impressive correlations with both subjective and objective measures of 
adherence and provide explanations for non-adherence, which were not found in 
other questionnaires such as the BMQ and PAM. Moreover, when exploring the 
variance in adherence scores, the model with the INAS scales outperforms these 
two widely used measures. 
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Looking at the content of the items in the two INAS subscales, it is apparent that the 
items cover a number of linked themes. The highest loading items in the Resisting 
Illness (RI) sub-scale relate to a reluctance to take medicines regularly because they 
serve as a constant reminder to the person that they have an illness together with a 
desire to feel normal again, as well as various concerns about the effects of the 
medicines. The Testing treatment (TT) sub-scale includes items reflecting the desire 
to omit or reduce treatment for a number of reasons, and reflect what Pound et al 
(14) describe as a preference to minimise the intake of medicine.  
 
The content of these two scales provides some insight into the pattern of scores 
found across the three illness groups. The similar pattern of INAS scores in the 
Oncology and Hypertension samples was something of a surprise but there are 
some possible explanations for this. In both conditions medication is taken for 
preventive purposes rather than to alleviate day to day symptoms. Moreover, both 
types of treatment can cause side effects. In contrast, in Gout the urate lowering 
medication has a direct effect on the underlying disease process and its regular use 
results in relief from the pain of gout. Thus, the lower INAS scores in these patients 
may well reflect the fact that taking this treatment can restore normality rather than 
challenge it. To confirm these hypotheses about the patterning of INAS scores 
across different illnesses as well as their predictive validity, it will be important to use 
the measure in patients with a range of other physical and mental health problems. 
 
The pattern of statistical association with the other measures included is also 
revealing. The fact that both INAS scales correlate with the Concerns scale of the 
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BMQ confirms that both tap into a range of underlying worries that people have 
about having to take medication (19). Whereas the BMQ Concerns scale focuses 
more on the negative effects of the medicines themselves, the INAS reveals some 
broader issues about medicine-taking as a threat to the self-system and that the 
mere fact of having to take medicines can act as a reminder of the underlying sick 
self. In contrast, the absence of any correlation with the BMQ Necessity scale 
indicates that the INAS is not tapping into patients’ evaluations of the need for their 
treatment per se but is assessing something much more strongly linked with their 
negative view of its perceived impact on their identity. Also the TT sub-scale seems 
to provide insights into a more dynamic process, in which the individual actively 
experiments with their level of medicine-taking to see if they can get away with taking 
less or even no treatment, possibly to see if the illness is still present. This may be 
particularly salient for those patients taking medicines for primarily preventive 
purposes or for those whose treatment has succeeded in reducing or eliminating the 
daily symptoms of their condition. 
 
The concepts captured by the INAS could be used to inform targeted treatment 
approaches. The sub-scales of the measure appear broadly to be commensurate 
with established (extended Common-Sense Model; [19]) and emergent 
(Psychological Flexibility; Acceptance and Commitment Therapy [20,21,22]) 
psychological intervention models. For example, the “Testing Treatment” sub-scale 
could be used, in addition to the BMQ, to inform the provision of tailored educational 
materials that challenge unhelpful beliefs about medication as a threat to one’s 
lifestyle. Whereas, if results from the “Resisting Illness” sub-scale suggest that 
medicine taking threatens one’s identity or that non-adherence stems from a difficulty 
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in tolerating discomfort (e.g. emotive memories or thoughts about illness), then, for 
example, techniques derived from Acceptance and Commitment Therapy could be 
applied. The latter uses aspects of mindfulness and behaviour change methods to 
help a person notice how getting caught up in unhelpful thoughts (cognitive fusion) 
and self-stories (attachment to a conceptualised self), or attempting to avoid 
discomfort (experiential avoidance) can lead to ineffective behaviour, which may 
include non-adherence, and then to make more effective decisions (20). 
 
As a preliminary study of a new scale for explaining different aspects of intentional 
non-adherence, this paper has a number of limitations. The psychometric analyses 
need to be extended to include additional tests of reliability and validity in other 
patient groups as well as in other countries and cultural settings. The INAS would 
also benefit from further evaluation of its factor structure by, for example, conducting 
confirmatory factor analysis. We are planning similar studies with different clinical 
populations as well as exploring the types of intervention which could successfully 
target the reasons for non-adherence revealed by the INAS. Mindful of the need for 
adherence interventions to be matched to patient determinants (23), it will be a 
challenge to develop novel approaches, which are able to address the adherence 
determinants revealed by the INAS.  
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Table 1. Results of the exploratory factor analysis of the INAS for the total sample  
( n = 275; Oncology = 115; Hypertension= 74; Gout=196 ) 
INAS-item Factor 1 
(Resisting    
Illness) 
       Factor 2     
(Testing           
treatment) 
1. To see if my illness is still there  .61 
2. To see if I can do without it   .95 
3. To see if I really need it    .91 
 
4. Because I am not convinced that the medicine is really right for 
me   
 
5. To give my body a rest from the medicine 
  
.73 
 
 
.79 
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6. Because my body is sensitive to the effects of medicine  .60  
7. Because I worry about becoming dependent on my medicine .68  
8. Because I want to think of myself as a healthy person again .78  
9. Because it reminds me that I have an illness .88  
10. Because I want to lead a normal life again .78  
11. Because it is good not to have to remember .86  
12. Because it is inconvenient to take all the time .85  
13. Because the drug schedule doesn’t fit with my lifestyle .77  
 
NB the reported loadings shown above are factor pattern coefficients 
 
 
 
 
 
 
 
Table 2. Correlations between subtotal scores from the two INAS factors and  
measures of adherence and illness perception (BIPQ) 
  INAS 
Testing 
Treatment 
  
INAS 
Resisting 
Illness 
   
Oncology and hypertension samples (N=189)   
BMQ Necessity          -.01             -.08 
BMQ Concern .52** .41** 
MARS 
 
-.56** -.55** 
(i) Gout sample (n=107)   
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BIPQ Consequences                                                                         
BIPQ Timeline 
 .31** 
         -.01 
.20* 
                 .03 
BIPQ Personal Control           .03                 .00 
BIPQ Treatment Control           .08                 .04 
BIPQ Identity             .25*                 .19* 
BIPQ Concerns 
BIPQ Understanding  
          . 24* 
          .00 
               .19 
                 .08 
BIPQ Emotional Response  .39** .33** 
 
Serum Urate (biomarker) 
 
.43** 
 
.43** 
 
** p<.001  *p<.05 
 
 
 
Table 3. Results of the multiple linear regression for (i) the association 
between adherence self-report (MARS), medication beliefs (BMQ) and INAS in 
the combined Oncology and Hypertension samples (N=189); (ii) the 
association between MARS, patient activation(PAM), medication beliefs (BMQ) 
and INAS in another Hypertension sample (N=101). 
 (i) 
 Unstandardized  
B 
Sig.  Model      
R2 
Model  1   .02 
   Gender -.31 .08  
   Age  .03 .55  
   Diagnosis  
 
.25 .64  
Model 2   .15 
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   Gender -.18 .70  
   Age  .02 .20  
   Diagnosis  .33 .50  
   BMQ Necessity  .10 .30  
   BMQ Concern 
  
-.38 <.001  
Model 3   .37 
   Gender -.09 .83  
   Age  .01 .73  
   Diagnosis .17 .68  
   BMQ Necessity  .01 .98  
   BMQ Concern  -.08 .29  
   INAS Resisting Illness”. -.13 .001  
   INAS Testing Treatment -.20 .001  
Model 1: clinical and demographic variables. Model 2: clinical, demographic and beliefs about 
medicine  variables. Model 3: clinical, demographic, beliefs about medicine variables and intention to 
non-adherence variables . 
(ii) 
Variable   estimate p value 
Model R
2 
Age   .03 .18 .44 
Gender   .73 .19  
PAM-13   .05 .11  
BMQ-Necessity Scores   .02 .82  
BMQ-Concern Scores - .06 .28  
Testing treatment - .20 .036  
Resisting Illness  -.10 .013  
----------------------------------------------------------------------------------------------------------------------------- ----- 
 
Table 4. Mean and Standard Deviation for the INAS subscales according to  
patient groups. 
 
Patient groups  Resisting    Illness  
Mean (SD) 
Testing Treatment  
Mean (SD) 
Oncology                          18.20 (8.19)                    10.39 (4.94) 
Hypertension                          18.70 (7.65)                    10.46 (4.82) 
Gout                          14.28 (6.95)                          8.96 (4.91) 
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Appendix 1. Mean scores and (standard deviation) for the 22 item INAS in 189 
outpatients (Oncology n = 115; Hypertension n = 74) 
1.To see if my illness is still there       1.81  (1.02) 
2.To see if I can do without it        2.21  (1.16)  
3.To see if I really need it        2.12  (1.15) 
4.Because I am not convinced that the medicine is really right for me   2.07  (1.07)  
5.Because I am not sure that the doctor chose the right medicine for me   1.99  (1.04) 
6.To give my body a rest from the medicine      2.25  (1.23)  
7.Because the medicine is harsh on my body      2.51  (1.32)  
8.Because I don’t like the medicine to accumulate in my body    2.34  (1.18)  
9.Because my body is sensitive to the effects of medicine    2.60  (1.33)  
10.Because I don’t like the side effects       2.82  (1.46)  
11.Because I don’t like chemicals in my body      2.43  (1.21)  
12.Because it may affect the body’s own natural healing processes   2.37  (1.15)  
13.Because I think I am on too high a dose      2.21  (1.09)  
14. Because I think the drug might become less effective over time   2.22  (1.07)  
15. Because I worry about becoming dependent on my medicine   2.21  (1.12)  
16.Because I want to think of myself as a healthy person again    2.26 (1.16)  
17. Because it reminds me that I have an illness     2.18  (1.07)  
18. Because I want to lead a normal life again      2.50  (1.22)  
19. Because it is good not to have to remember      2.21  (1.14)  
20.Because it is inconvenient to take all the time     2.34  (1.28) 
21. Because the drug schedule doesn’t fit with my lifestyle    1.76  (.88)  
22. Because I don’t think the treatment is worth it    1.61  (.83) 
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Highlights 
 The INAS contains two new scales assessing reasons for non-adherence to 
treatment. 
 Patients may not adhere because they do not want to be reminded of their 
illness 
 Others attempt to see if they can get away with taking less or no treatment.  
 Both factors explain unique variance in subjective and objective adherence 
markers 
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